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ABSTRACT 
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of the survival 
motor neuron (SMN) gene. While there are currently two approved gene-based therapies for 
SMA, availability, high cost, and differences in patient response indicate that alternative 
treatment options are needed. Optimal therapeutic strategies will likely be a combination of 
SMN-dependent and -independent treatments aimed at alleviating symptoms in the central 
nervous system and peripheral muscles. Krüppel-like factor 15 (KLF15) is a transcription factor 
that regulates key metabolic and ergogenic pathways in muscle. We have recently reported 
significant downregulation of Klf15 in muscle of pre-symptomatic SMA mice. Importantly, 
perinatal upregulation of Klf15 via transgenic and pharmacological methods resulted in 
improved disease phenotypes in SMA mice, including weight and survival. In the current study, 
we designed an adeno-associated virus serotype 8 (AAV8) vector to overexpress a codon-
optimised Klf15 cDNA under the muscle-specific Spc5-12 promoter (AAV8-Klf15). 
Administration of AAV8-Klf15 to severe Taiwanese Smn-/-;SMN2 or intermediate Smn2B/- SMA 
mice significantly increased Klf15 expression in muscle. We also observed significant activity 
of the AAV8-Klf15 vector in liver and heart.  AAV8-mediated Klf15 overexpression moderately 
improved survival in the Smn2B/- model but not in the Taiwanese mice. An inability to 
specifically induce Klf15 expression at physiological levels in a time- and tissue-dependent 
manner may have contributed to this limited efficacy. Thus, our work demonstrates that an 
AAV8-Spc5-12 vector induces high gene expression as early as P2 in several tissues including 
muscle, heart and liver, but highlights the challenges of achieving meaningful vector-mediated 
transgene expression of Klf15.  
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INTRODUCTION 
Spinal muscular atrophy (SMA) is a devastating childhood neuromuscular disease that leads 
to early death in the most severe cases 1,2. As an autosomal recessive disease, SMA is caused 
by loss of the survival motor neuron 1 (SMN1) gene due to either mutations or deletions 3. 
While a total deficiency in the SMN protein is embryonic lethal 4, humans have a duplicated 
copy of SMN1, termed SMN2 3, which allows for survival in the absence of the former. 
However, SMN2 contains a key C to T transition in exon 7 that leads to its excision in 
approximately 90% of the transcripts produced, generating a non-functional SMN7 protein 
that is rapidly degraded 5,6. Importantly, the 10% of fully functional full length SMN protein 
produced from SMN2 is sufficient to allow survival, albeit not sufficient to prevent 
neuromuscular degeneration 7. 
The first genetic therapy for SMA, nusinersen/Spinraza™, was approved in December 2016 
by the Food and Drug Administration (FDA) and in June 2017 by the European Medicines 
Agency 8. This antisense oligonucleotide is delivered directly to the central nervous system 
(CNS) via a lumbar puncture and is aimed at promoting SMN2 exon 7 inclusion 9. Zolgensma® 
is a single, systemic of delivery of SMN1 via an adeno-associated virus serotype 9 (AAV9) 
gene therapy that received FDA approval in May 2019 10. Additional SMN-enhancing 
pharmacological compounds are also in the pipeline and anticipated to be approved for patient 
use in the near future 11. While the benefits of these SMN-dependent drugs are undeniably 
remarkable, it is appreciated that they unfortunately do not represent a cure and will have to 
be supported by additional non-CNS and -SMN therapeutic interventions to provide optimal 
care to all SMA patients 12–15. 
Skeletal muscle with reduced levels of SMN displays both cell-autonomous and non-
autonomous defects 16,17 and is therefore an important therapeutic target for SMA. We have 
recently demonstrated the dysregulated expression of the transcription factor Krüppel-like 
factor 15 (Klf15) in skeletal muscle of SMA mice during disease progression 18. KLF15 is 
crucial in the regulation of skeletal muscle metabolism and ergogenic properties 19–22. 
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Specifically, we observed a significant downregulation of Klf15 expression in pre-symptomatic 
SMA mice and found that its neonatal upregulation via pharmacological (prednisolone) or 
transgenic (muscle-specific Klf15-overexpression) interventions significantly improved several 
disease phenotypes in SMA mice 18. However, prednisolone has pleiotropic activities and 
constitutive embryonic overexpression of Klf15 in skeletal muscle of SMA may have resulted 
in compensatory mechanisms 23. In this study, we thus set out to overexpress Klf15 in skeletal 
muscle of neonatal SMA mice via a self-complementary adeno-associated virus serotype 2/8 
and the Spc5-12 promoter. While this strategy led to substantial Klf15 expression in skeletal 
muscle of SMA mice and control littermates, there were no associated significant 
improvements in disease phenotypes. Nevertheless, AAV8-Klf15 injections resulted in 
pronounced expression as early as post-natal day 2 in several tissues including muscle, liver 
and heart, highlighting the potential of this specific viral construct for efficient perinatal delivery.  
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MATERIALS AND METHODS 
Animals 
Wild-type (WT) FVB/N mice were used for initial expression screening. The Taiwanese Smn-
/-;SMN2 (FVB/N background, FVB.Cg-Smn1tm1HungTg(SMN2)2Hung/J, RRID: J:59313) 24 
and the Smn2B/- 25 mice (generously provided by Dr Lyndsay M Murray, University of 
Edinburgh) were housed in individual ventilated cages (fed ad libitum, 12 hr light: 12 hr dark 
cycle) at the Biomedical Sciences Unit, University of Oxford, according to procedures 
authorized by the UK Home Office (Animal Scientific Procedures Act 1986). The viral 
constructs were diluted in sterile 0.9% saline and administered at the indicated dose at 
postnatal day (P) 0 by a facial vein intravenous injection 26. Litters were randomly assigned to 
treatment at birth. For survival studies, animals were weighed daily and culled at indicated 
time points or upon reaching their defined humane endpoint as set out by the Home Office 
Project Licence. For the Smn2B/- mice, weaned mice were given daily wet chow at the bottom 
of the cage to ensure proper access to food. Sample sizes were determined based on similar 
studies with SMA mice. 
 
Sc-AAV2/8-Spc5-12 constructs 
The generation of the self-complementary adeno-associated virus serotype 2/8 (scAAV2/8) 
vectors and quality control were performed by Atlantic Gene Therapies (Nantes, France). The 
synthetic Spc5-12 promoter 27 was used to drive the expression of eGFP or a codon-optimised 
Klf15 sequence: 
agcgcttcaccacaggctcggccaggccagcatggttgatcatctgctgcctgtggacgagacattcagcagccctaagtgttct
gtgggctacctgggcgacagactggcctctagacagccttaccacatgctgccctctccaatcagcgaggacgactccgatgtgt
ctagcccttgtagctgtgcctctcctgacagccaggccttctgtagctgttactctgctggacctggacctgaggctcagggctctatc
ctggatttcctgctgagcagagctacactcggctctggcggaggatctggcggaatcggagattcttctggccctgtgacatgggg
ctcttggagaagggctagcgtgcccgtgaaagaggaacacttctgcttccctgagttcctgagcggcgacaccgatgacgtgtcc
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agacctttccagcctacactggaagagatcgaagagttcctcgaagagaacatggaagccgaagtgaaagaagcccctgag
aacggctcccgcgacctggaaacatgttctcagctgtctgccggctctcacagaagccatctgcaccctgaaagcgccggcag
agagagatgtacacctcctccaggtggaacatctggcggcggagcacaatctgctggcgaaggacctgctcatgatggacctg
tgcctgtgctgctgcaaatccagcctgtggctgtgaagcaagaggctggaacaggaccagcttctcctggacaggctcctgaatc
tgtgaaggtggcccagctgctggtcaacatccagggacaaacattcgccctgctgcctcaggtggtgcccagcagtaatctgaa
cctgcctagcaagttcgtgcggatcgctcctgtgccaatcgctgctaagcctatcggatctggctctcttggtcctggaccagctgga
ctgctcgtgggacagaagttccctaagaaccctgccgccgagctgctgaagatgcacaagtgtacattccccggctgctccaag
atgtataccaagtcctctcacctgaaggcccacctgagaaggcataccggcgagaagcctttcgcttgcacatggcctggatgtg
gctggcggttcagcagatctgatgagctgagcaggcaccgcagatctcacagcggagtgaagccataccagtgtcctgtgtgc
gagaagaagttcgccagaagcgaccacctgtccaagcacatcaaggtgcacagattccctagaagcagcagagccgtgcgg
gccatcaattgactgcagaagctt. 
 
C2C12 cell line 
C2C12 myoblast cells 28 were maintained in growth media consisting of Dulbecco’s Modified 
Eagle’s Media (DMEM) supplemented with 10% fetal bovine serum and 1% 
Penicillin/Streptomycin (all Life Technologies). For AAV transduction experiments, growth 
media was changed to differentiation media consisting of DMEM, 2% horse serum, and 1% 
Penicillin/Streptomycin (all Life Technologies). Cells were allowed to differentiate for 3 days, 
after which they were transduced with a MOI of 1E105. Cells were harvested 3 days post-
transduction for molecular analyses (flow cytometry or qPCR, as described below). 
 
qPCR 
Quadriceps muscles, liver, and heart were harvested at the indicated time points during 
disease progression and immediately flash frozen. RNA was extracted with the RNeasy 
MiniKit (Qiagen). For C2C12 cells, the media was removed and cells were washed with PBS 
before being directly lysed as per instructions within the RNeasy MiniKit (Qiagen). Reverse 
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transcription was performed using the High-Capacity cDNA Reverse Transcription Kit 
(ThermoFisher Scientific). qPCR was performed using SYBR green Mastermix (ThermoFisher 
Scientific) and primers for the codon-optimised Klf15 sequence (Forward: 
AGGACCTGCTCATGATGGAC; Reverse: TGTTTGTCCCTGGATGTTGA). RNA polymerase 
II polypeptide J (PolJ), was used as a validated stably expressed housekeeping gene 29 
(Forward: ACCACACTCTGGGGAACATC; Reverse: CTCGCTGATGAGGTCTGTGA). All 
primers were ordered from Integrated DNA Technologies. 
 
Viral quantification 
In order to establish virus penetration into the tissue, TaqMan (ThermoFisher Scientific) 
qPCRs were performed using two primer-probe sets (Integrated DNA Technologies) specific 
to the AAV8 capsid (1: Forward: GCTCTTCAACATCCAGGTCAA; Reverse: 
TGGTACTCCGAGTCCGTAAA; Probe: TGGTACTCCGAGTCCGTAAA; and 2: Forward: 
GACCACCTTCAACCAGTCAA; Reverse: CTGCAGCTCCCATTCAATTTC; Probe: 
TTCATCACGCAATACAGCACCGGA). The results of the two primer-probe sets were each 
efficiency-adjusted and normalized to PolJ (Forward: GTGGTCTTCTTTGTTGATGGTG; 
Reverse: TTCGAGTCGTTCTTGCTCTTC; Probe: AAGCAGGCGTTGGGAACCTTAGT). The 
two primer-probe sets yielded similar results (data not shown) and only data with primer set 2 
are shown. No significant difference was detected between Smn+/-;SMN2 and Smn-/-;SMN2 
mice for any of the tissues (data not shown) and mice from both genotypes were therefore 
pooled. No amplification could be seen in untreated samples (data not shown). 
 
Flow cytometry 
Differentiated C2C12 cells 3 days post-transduction (AAV8-GFP, MOI of 1E105)  and 
untreated cells were trypsinized and washed in fluorescence-activated cell sorting (FACS) 
buffer (phosphate buffered saline (PBS) supplemented with 2% bovine serum albumin (BSA) 
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and 0.05% sodium azide). Cells were pelleted by centrifugation at 300 x g for 5 minutes. The 
final cell pellet was resuspended in 200  of FACS buffer and the cell suspension was further 
diluted 1:2 in FACS buffer before detection in the Cytek DxP8 flow cytometer (Cytek® 
Biosciences). Cell viability was tested by adding 1 µl Sytox Red (Thermofisher) to the final cell 
suspension for 5 minutes at RT. The gating strategy included gating around the Sytox Red 
(RedFL1 channel) negative population following FCS/FCSW doublet exclusion. The remaining 
population was assessed for a GFP-shift by recording in the BluFL1 channel. A total of 10,000 
cells was recorded for each sample replicate. Data was analysed using Flowjo 10 software 
(TreeStar Inc.). 
 
Immunocytochemistry and immunohistochemistry 
C2C12 cells transduced with the eGFP-expressing AAV vector were imaged live with a DM 
IRB microscope (Leica). 
Quadriceps muscles were harvested at the indicated time points during disease progression, 
fixed in 4% paraformaldehyde, cryopreserved in 30% sucrose, and cryosectioned at a 
thickness of 12 M. The sections were immunostained with chicken anti-GFP antibody 
(1:3000, Abcam, ab13970) and detected with Alexa-488-conjugated anti-chicken secondary 
antibody (1:5000, Life technologies, A-11039). Images were taken with an Olympus Fluoview 
FV1000 confocal microscope and processed with Fiji 30. 
 
Statistics 
All statistical analyses were performed using GraphPad Prism version 8.1.1 software. Exact 
sample sizes as well as description of sample collection, number of times the experiments 
were replicated and statistical measures and methods can be found in the figure legends. 
When appropriate, a Student’s unpaired two-tailed t test or a two-way ANOVA followed by an 
uncorrected Fisher's LSD multiple comparison test was used. Outliers were identified via the 
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Grubbs' test and subsequently removed. Instances of outlier removal are detailed in the 
relevant figure legends. For the Kaplan-Meier survival analysis, a log-rank test was used. 
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RESULTS 
Muscle-specific Klf15 expression with a scAAV2/8-Spc5-12 viral vector 
To specifically induce Klf15 expression in skeletal muscle, we utilized a self-complementary 
adeno associated virus serotype 2/8 driven by the synthetic muscle-specific promoter Spc5-
12 27 (scAAV2/8-Spc5-12-Klf15, henceforth termed AAV8-Klf15). This combination of AAV and 
promoter has previously successfully been used for gene delivery to muscles for treatment of 
the muscle disorder Duchenne muscular dystrophy (DMD) 31. A control scAAV2/8-Spc5-12-
GFP construct was also generated (henceforth termed AAV8-GFP). 
We first examined the transduction ability of the AAV8-GFP construct in differentiated C2C12 
myoblasts 28. The cells were transduced with AAV8-GFP (multiplicity of infection (MOI) 1E105) 
for 3 days and assessed for GFP expression compared to untreated cells. Both flow cytometry 
and live imaging analyses confirm the abundant presence of GFP in AAV8-transduced cells 
(FIG. 1A, 1B). Differentiated C2C12s transduced with AAV8-Klf15 (MOI 1E105) demonstrate 
a significant increased expression of Klf15 mRNA compared to untreated cells (FIG. 1C). 
To determine if our constructs would also be active at early time points in muscle of neonatal 
mice, we administered AAV8-GFP (1E11 vg/pup) to P0 wild type (WT) pups via a facial vein 
intravenous injection 26. Quadriceps muscles were harvested from injected and non-injected 
WT littermates at P2 and P7. P2 represents the pre-symptomatic age at which we have 
observed a significant downregulation of Klf15 in the Taiwanese Smn-/-;SMN2 SMA mice 18,24 
while P7 is considered a late symptomatic time point. qPCR analysis shows a significant 
upregulation of GFP expression at both P2 and P7, albeit variable between animals, with 
increased levels at the later time point (FIG. 1D). Immunohistochemistry of P2 and P7 
quadriceps also reveals a time-dependent increased expression of GFP in AAV8-treated 
animals compared to untreated littermates (FIG. 1E). Combined, our experiments in C2C12s 
and WT mice demonstrate the ability of our viral vectors to induce Klf15 and GFP expression 
in differentiated skeletal muscle. 
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Neonatal administration of AAV8-Klf15 to severe SMA mice does not improve weight or 
survival 
We next wanted to determine if increasing early postnatal Klf15 expression in the Smn-/-;SMN2 
SMA mice would influence disease progression. However, administration of 1E11 vg/pup of 
AAV8-Klf15 to P0 Smn-/-;SMN2 mice and Smn+/-;SMN2 control littermates was in fact toxic 
(spontaneous death without any impact on weight) to both genotypes (data not shown). Seeing 
as this dose was not harmful with AAV8-GFP, the adverse effects are most likely due to the 
supraphysiological levels of Klf15. We therefore reduced the AAV8-GFP and AAV8-Klf15 dose 
to 2E10 vg/pup for subsequent administrations, which still allowed for an age-dependent 
increased expression of GFP (FIG. 2A) and Klf15 (FIG. 2B), albeit with some variability 
between animals, in quadriceps of P2 and P7 Smn+/-;SMN2 and Smn-/-;SMN2 mice. 
In terms of effects on disease progression, we found that AAV8-Klf15-treated Smn-/-;SMN2 
mice survived longer than untreated Smn-/-;SMN2 (FIG. 2C). However, AAV8-GFP-treated 
Smn-/-;SMN2 mice also display a moderately improved lifespan (FIG. 2C), suggesting that the 
AAV construct itself has some beneficial physiological impact. Interestingly, we also observed 
that Smn-/-;SMN2 mice that received the AAV8-GFP weighed slightly more than AAV8-Klf15-
treated and untreated Smn-/-;SMN2 (FIG. 2D). 
We found no significant differences between the survival of untreated, AAV8-GFP-treated and 
AAV8-Klf15-treated Smn+/-;SMN2 mice (FIG. 2E), although a small number of spontaneous 
deaths occurred in all cohorts. Similar to what we observed in the Smn-/-;SMN2 mice, AAV8-
GFP-treated Smn+/-;SMN2 mice weighed slightly more than untreated and AAV8-Klf15-treated 
Smn+/-;SMN2 mice during the P0–P21 pre-weaning phase (FIG. 2F). However, this increased 
weight was not maintained post-weaning (FIG. 2G). We did observe a small but significant 
increase in weight of AAV8-Klf15-treated Smn+/-;SMN2 mice at 6 months of age. Thus, 
administering a perinatal injection of AAV8-Klf15 at a dose of 2E10 vg/pup significantly 
increases Klf15 expression in skeletal muscle without having overt adverse or beneficial 
effects on survival. Of note, a smaller AAV8-Klf15 dose of 1E10 vg/pup was also assessed 
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but did not display significant survival benefits compared to the 2E10 vg/pup dose 
(Supplementary FIG. 1).  
 
Neonatal administration of AAV8-Klf15 to intermediate SMA mice slightly improves 
survival 
Due to the severe and rapid disease progression in the Smn-/-;SMN2 mice, they respond less 
favorably to non-SMN treatment strategies compared to the milder intermediate Smn2B/- 
mouse model 18,25,32,33. We therefore proceeded to evaluate the effect of AAV8-Klf15 in Smn2B/- 
mice and Smn2B/+ control littermates, following the same dosing regimen as in the severe SMA 
mice. Similar to what was observed in the Smn-/-;SMN2 mice, AAV8-GFP-treated Smn2B/- mice 
also demonstrated a small but significant increase in survival compared to untreated Smn2B/- 
mice (FIG. 3A). Interestingly, AAV8-Klf15-treated Smn2B/- mice had a significantly increased 
lifespan compared to both untreated and AAV8-GFP-treated Smn2B/- mice (FIG. 3A). While 
AAV8-Klf15 did not influence the weight of Smn2B/- mice compared to untreated and AAV8-
GFP-treated animals during the nursing period (up to P21), post-weaned mice demonstrate a 
growth-dependent gain in weight (FIG. 3B). However, that weight gain did not ultimately 
prevent an early death. Interestingly, AAV8-GFP-treated Smn2B/- mice were significantly 
heavier than untreated and AAV8-Klf15-treated Smn2B/- mice (FIG. 3B) between P13–21, 
again similar to what we found in the Smn-/-;SMN2 mice. We did not observe any effects of 
AAV8-GFP or AAV8-Klf15 on the weights of pre-weaned Smn2B/- mice compared to untreated 
animals (FIG. 3C). Thus, the AAV8-Klf15 was slightly more beneficial in the intermediate 
Smn2B/- SMA mouse model than the severe Taiwanese Smn-/-;SMN2 mice, overall. 
 
The AAV8-Spc5-12 construct also induces expression in heart and liver 
While the synthetic Spc5-12 promoter has been used for its enhanced activity in skeletal 
muscle 27,31, we wanted to determine if our AAV8 delivery system also induced expression in 
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heart and liver, tissues in which Klf15 also plays key roles 34,35. We indeed observed significant 
increased expression of GFP and Klf15 mRNA in the livers of both P2 and P7 AAV8-GFP- 
(FIG. 4A) and AAV8-Klf15-treated (FIG. 4C) Smn+/-;SMN2 and Smn-/-;SMN2 mice compared 
to untreated animals. This increase was approximately 15 times (GFP) and 10 times (Klf15) 
higher than in skeletal muscle for both time points. Similarly, we find a significant upregulation 
of GFP and Klf15 mRNA in the hearts of AAV9-GFP- (FIG. 4C) and AAV8-Klf15-treated (FIG. 
4D) P2 and P7 Smn+/-;SMN2 and Smn-/-;SMN2 mice compared to untreated animals. 
Surprisingly, the increase in heart was approximately 40 times (GFP) and 50 times (Klf15) 
higher at P2 while it was approximately 70 times (GFP) and 10 times (Klf15) higher at P7 
compared to skeletal muscle at those respective time points. Furthermore, qPCR analysis of 
AAV8 content in respective tissues, using capsid-specific primers, indeed demonstrates 
increased AAV8 presence in heart and liver compared to muscle, particularly at P2 
(Supplementary FIG. 2). Of note, there was some variability between animals within the same 
experimental group. Therefore, our results demonstrate that the activity of the AAV8-Spc5-12 
vector is not exclusive to skeletal muscle and in fact, appears to display a greater tropism for 
non-skeletal muscle tissues when administered intravenously in newborn animals. 
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DISCUSSION 
We have recently demonstrated that Klf15 expression is significantly downregulated in muscle 
of pre-symptomatic SMA mice and that upregulating Klf15 expression via genetic (transgenic 
muscle-specific expression) or pharmacological (prednisolone) approaches results in 
improved disease phenotypes 18. Here, we evaluated the impact of specifically upregulating 
Klf15 in skeletal muscle in perinatal mice by driving its expression via an AAV8-Spc5-12 
vector. We find that while neonatal administration of the AAV8-Klf15 construct leads to 
significant increased levels of Klf15 in muscle, this has no overt effect on survival or weight 
gain in the severe Taiwanese SMA mice while we observe a small improvement in the lifespan 
of the intermediate Smn2B/- mice. 
The lack of significant impact of AAV8-Klf15 in severe SMA mice may be due to several 
compounding factors. While the levels of Klf15 expression achieved with AAV8-Klf15 are 
similar to the levels observed in transgenic SMA mice overexpressing muscle-specific Klf15 
at P2 (~ 5–10 fold greater than control littermates), the amounts measured in P7 AAV8-Klf15-
treated animals are significantly greater than the transgenic mice (~ 65–740 fold greater and 
~ 30 fold greater, respectively, compared to control littermates) (FIG. 2) 18. As Klf15 can display 
both atrophy-inducing 36 and ergogenic 19 properties in skeletal muscle in a dose-dependent 
manner 37, it is quite possible that the supraphysiological levels achieved with AAV8-Klf15 
favor muscle wasting over growth. We also note significantly more variability in Klf15 levels in 
animals injected with the AAV8 construct compared to the transgenic mice (FIG. 2) 18, which 
are most likely due to differential injection efficiencies and/or vector spread and could influence 
physiological outcomes. 
We have previously shown that administration of prednisolone to SMA mice also increases 
Klf15 levels in skeletal muscle of P2 pre-symptomatic animals (~ 6 fold greater than untreated 
controls) 18. However, this effect on Klf15 induction ceased at P7, specifically in SMA mice 18, 
suggesting that prednisolone-dependent benefits in symptomatic SMA mice may be due to 
KLF15-independent effects and/or that prednisolone-dependent Klf15 increase in P7 animals 
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may be limited by compensatory inhibitory mechanisms due to already significantly increased 
Klf15 levels in symptomatic SMA mice compared to controls 18. It is therefore possible that an 
optimal strategy would be to conditionally increase Klf15 expression in pre-symptomatic 
stages only, which is not easily achieved as the kinetics of AAV-mediated overexpression 
require several days for efficient transgene activity. To achieve optimal expression at early 
pre-symptomatic post-natal stages may therefore require pre-natal delivery. 
While our AAV8 construct was designed to overexpress Klf15 specifically in skeletal muscle, 
our analysis of heart and liver demonstrate significantly higher activity in these tissues (FIG. 4 
and Supplementary FIG. 2). Tropism of the AAV8 construct and the Spc5-12 promoter, alone 
and in combination, has indeed previously been reported in both the heart and liver of adult 
mice 31,38. Our data supports that this is also the case in neonatal mice. KLF15 has well 
described roles in heart and liver 34,35, suggesting that its increased expression via our AAV8 
construct, most likely also impacts the function of these tissues. SMA mice display several 
heart and liver pathologies 39,40, suggesting that aberrant KLF15 levels may have non-intended 
organ-specific adverse effects, which most likely explain the spontaneous deaths observed in 
our mice treated with the high vector dose. Furthermore, we have previously reported 
increased levels of Klf15 in the liver and heart of symptomatic mice 18, which most likely reflect 
a pathological response. However, as only one preparation of AAV8-Klf15 was used 
throughout this study, its toxicity may have been due to batch-specific impurities 41. However, 
seeing as the toxicity of AAV8-Klf15 was dose-dependent in both compromised SMA mice 
and healthy littermates and not observed in parallel experiments with AAV8-GFP, it is most 
likely that the adverse effects were directly linked to the supraphysiological levels of Klf15 in 
several key metabolic tissues such as muscle, heart and liver. Thus, the dose-dependent 
effects of AAV8-Spc5-12-mediated Klf15 upregulation are probably due to a complex interplay 
between tissue- and age-dependent beneficial and adverse signaling pathways that should 
be considered and evaluated in future investigations.  
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Surprisingly, the AAV8-GFP construct also demonstrated some non-negligible effects on 
disease phenotypes of SMA mice (FIG. 3). While we cannot be certain as to why that is, we 
speculate that it may be related to possible effects on the immune system, similarly to previous 
reports for AAV8 vectors 42,43. Seeing as SMA mice have an altered immune response 44,45 
and that inflammation can display both protective and adverse systemic properties 46, including 
the CNS 47 and muscle 48, it is possible that an activated immune response results in acute 
and/or intermittent benefits in AAV8-treated SMA animals. 
In summary, the limited impact of AAV8-Klf15 administration in SMA mice might be explained 
by several experimental conditions that most likely reduced our ability to increase Klf15 
specifically in skeletal muscle at physiological levels and with the optimal timing, without 
influencing the function of other tissues and systems. In the experimental paradigms tested 
here, the positive, albeit small, effect on survival and weight was restricted to the milder 
Smn2B/- SMA mouse model. Future investigations will require endeavors to further optimize a 
muscle-specific construct by either reconfiguring the AAV/promoter combination and/or 
inhibiting its expression in non-skeletal muscle tissues.  
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FIGURE LEGENDS 
FIG. 1. Muscle-enhanced expression with the scAAV2/8-Spc5-12-Klf15 and-GFP (AAV8-
Klf15 and AAV8-GFP) viral vectors. A. Mean GFP fluorescence intensity (arbitrary units) 
determined by flow cytometry analysis in differentiated C2C12s, untreated or transduced with 
AAV8-GFP (MOI 1E105) for 3 days. Data are scatter plot and mean  SEM, n = 3 wells per 
experimental group, unpaired t test, ****p<0.0001. B. Representative images (phase contrast 
and GFP fluorescent signal) of differentiated C2C12 cells 3 days post-transduction with AAV8-
GFP (MOI 1E105). C. qPCR analysis of Klf15 mRNA expression in differentiated C2C12s 3 
days post-transduction with AAV8-Klf15 (MOI 1E105) compared to untreated cells. Data are 
shown as scatter plot and mean  SEM, n = 3 wells per experimental group, unpaired t test, 
****p<0.0001. D. qPCR analysis of GFP mRNA expression in quadriceps muscles of post-
natal day (P) 2 and P7 wild type (WT) animals that received a facial intravenous injection of 
AAV8-GFP (1E11 vg/pup) at P0 compared to untreated WT mice. Data are scatter plot and 
mean  SEM, n = 4–5 animals per experimental group, unpaired t test, *p = 0.028 (P2), **p = 
0.0076 (P7). E. Representative images of cross-sections (P2) and longitudinal sections (P7) 
of quadriceps immunostained for GFP from P2 and P7 untreated WT animals and WT mice 
that received a facial intravenous injection of AAV8-GFP (1E11 vg/pup) at P0. 
 
FIG. 2. Perinatal administration of AAV8-Klf15 does not improve weight or survival of 
Smn-/-;SMN2 SMA mice. Post-natal day (P) 0 Smn-/-;SMN2 SMA mice and control littermates 
were either untreated or received a single facial vein intravenous injection of AAV8-GFP or 
AAV8-Klf15 (2E10 vg/pup). A. qPCR analysis of GFP mRNA expression in quadriceps of P2 
and P7 untreated and AAV8-GFP-treated Smn+/-;SMN2 and Smn-/-;SMN2 mice. Data are 
scatter plot and mean  SEM, n = 2–6 animals per experimental group, two-way ANOVA, 
**p<0.01, ***p<0.001. B. qPCR analysis of Klf15 mRNA expression in quadriceps of P2 and 
P7 untreated and AAV8-Klf15-treated Smn+/-;SMN2 and Smn-/-;SMN2 mice. Data are scatter 
plot and mean  SEM, n = 4–9 animals per experimental group, two-way ANOVA, *p<0.05, 
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***p<0.001, ****p<0.0001. One outlier identified by the Grubbs’ test was removed from the P7 
Smn-/-;SMN2 group C. Survival curves of untreated (n = 16), AAV8-GFP-treated (n = 9) and 
AAV8-Klf15-treated (n = 7) Smn-/-;SMN2 mice. Data are Kaplan-Meier survival curves, log-
rank Mantel-Cox test, ns = not significant, **p = 0.0034 (untreated vs AAV8-GFP), **p = 0.0048 
(untreated vs AAV8-Klf15). D. Daily weights of untreated (n = 16), AAV8-GFP-treated (n = 9) 
and AAV8-Klf15-treated (n = 7) Smn-/-;SMN2 mice. Data are mean  SEM, two-way ANOVA, 
*/^p<0.05, **/^^p<0.01, ***p<0.001, ****p<0.0001. E. Survival curves of untreated (n = 12), 
AAV8-GFP-treated (n = 7) and AAV8-Klf15-treated (n = 13) Smn+/-;SMN2 mice. Data are 
Kaplan-Meier survival curves, log-rank Mantel-Cox test, ns = not significant. F. Daily weights 
of untreated (n = 11), AAV8-GFP-treated (n = 8) and AAV8-Klf15-treated (n = 12) Smn+/-;SMN2 
mice. Data are mean  SEM, two-way ANOVA, */^/#p<0.05, **/^^p<0.01, ***/^^^p<0.001, 
^^^^p<0.0001. G. Monthly weights of untreated (n = 11), AAV8-GFP-treated (n = 7) and AAV8-
Klf15-treated (n = 13) Smn+/-;SMN2 mice. Data are mean  SEM, two-way ANOVA, *p<0.05.  
 
FIG. 3. Perinatal administration of AAV8-Klf15 slightly increases survival in Smn2B/- SMA 
mice. Post-natal day (P) 0 Smn2B/- SMA mice and control littermates were either untreated or 
received a single facial vein intravenous injection of AAV8-GFP or AAV8-Klf15 (2E10 vg/pup). 
A. Survival curves of untreated (n = 15), AAV8-GFP-treated (n = 18) and AAV8-Klf15-treated 
(n = 11) Smn2B/- mice. Data are Kaplan-Meier survival curves, log-rank Mantel-Cox test, **p = 
0.0021 (untreated vs AAV8-GFP), ****p<0.0001 (untreated vs AAV8-Klf15), ***p = 0.0008 
(AAV8-GFP vs AAV8-Klf15). B. Daily weights of untreated (n = 18), AAV8-GFP-treated (n = 
18) and AAV8-Klf15-treated (n = 11) Smn2B/- mice. Data are mean  SEM, two-way ANOVA, 
*/^/#p<0.05, **/^^p<0.01, ^^^p<0.001, ^^^^p<0.0001. C. Daily weights of untreated (n = 11), 
AAV8-GFP-treated (n = 9) and AAV8-Klf15-treated (n = 16) Smn2B/+ mice. Data are mean  
SEM, two-way ANOVA, ns = not significant. 
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FIG. 4. Perinatal administration of the AAV8-Spc5-12 construct induces high expression 
in liver and heart.  Post-natal day (P) 0 Smn-/-;SMN2 SMA mice and control littermates were 
either untreated or received a single facial vein intravenous injection of AAV8-GFP or AAV8-
Klf15 (2E10 vg/pup). A-B. qPCR analysis of GFP (A) and Klf15 (B) mRNA expression in 
quadriceps muscles of P2 and P7 untreated and AAV8-treated Smn+/-;SMN2 and Smn-/-;SMN2 
mice. Data are scatter plot and mean  SEM, n = 2–6 animals per experimental group, two-
way ANOVA, **p<0.01, ***p<0.001, ****p<0.0001. One outlier identified by the Grubbs’ test 
was removed from the P7 liver AAV8-Klf15 Smn-/-;SMN2 group. C-D. qPCR analysis of GFP 
(C) and Klf15 (D) mRNA expression in heart of P2 and P7 untreated and AAV8-treated Smn+/-
;SMN2 and Smn-/-;SMN2 mice. Data are scatter plot and mean  SEM, n = 2–8 animals per 
experimental group, two-way ANOVA, **p<0.01, **p<0.01, ***p<0.001 ****p<0.0001. One 
outlier identified by the Grubbs’ test was removed from the P2 heart untreated Smn-/-;SMN2 
group.  
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